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Abstract 93 
 94 
Background: Family history (FH) of pancreatic cancer (PC) has been associated with an increased 95 
risk of PC but little is known regarding the role of inherited/environmental factors or that of FH of 96 
other co-morbidities in PC risk. We aimed to address these issues using multiple methodological 97 
approaches.  98 
Methods: Case-control study including 1,431 PC cases and 1,090 controls and a reconstructed-99 
cohort study (N=16,747) made up of their first-degree relatives (FDR). Logistic regression was used 100 
to evaluate PC risk associated with FH of cancer, diabetes, allergies, asthma, cystic fibrosis and 101 
chronic pancreatitis by relative type and number of affected relatives, by smoking status and other 102 
potential effect modifiers, and by tumour stage and location. Familial aggregation of cancer was 103 
assessed within the cohort using Cox proportional-hazard regression.  104 
Results: FH of PC was associated with an increased PC risk (OR=2.68; 95%CI: 2.27–4.06) when 105 
compared to cancer-free FH, the risk being greater when ≥2 FDRs suffered PC (OR=3.88; 95%CI: 106 
2.96-9.73) and among current-smokers (OR=3.16, 95%CI: 2.56-5.78, interaction FHPC*smoking 107 
p-value=0.04). PC cumulative risk by age 75 was 2.2% among FDRs of cases and 0.7% in those 108 
of controls (HR=2.42; 95%CI: 2.16-2.71). PC risk was significantly associated with FH of cancer 109 
(OR=1.30; 95%CI: 1.13-1.54) and diabetes (OR=1.24; 95%CI: 1.01-1.52), but not with FH of other 110 
diseases.  111 
Conclusion: The concordant findings using both approaches strengthen the notion that FH of 112 
cancer, PC or diabetes confer a higher PC risk. Smoking notably increases PC risk associated with 113 
FH of PC. Further evaluation of these associations should be undertaken to guide PC prevention 114 
strategies. 115 
 116 
117 
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KEY MESSAGE (characters: 363) 118 
1. Complementary analytical approaches confirm that, regardless of non-genetic risk factors, 119 
risk of pancreatic cancer is by about two-and-a-half times higher among family members 120 
with more than two relatives affected with this disease, with this risk becoming stronger in 121 
current smokers.  122 
2. Family history of any cancer and of selected cancer types (e.g. prostate, multiple primaries, 123 
or the smoking-related ones) also confers higher risk of pancreatic cancer. 124 
3. Family history of diabetes mellitus is associated with a moderately increased risk of 125 
pancreatic cancer, mainly for advanced-stage tumours. 126 
4. The incorporation of detailed information on family history of pancreatic cancer and other 127 
related-medical conditions into risk prediction models will help to identify subgroups of the 128 
population among whom routine screening and surveillance programs could be considered 129 
in an effective and optimal way.  130 
 131 
  132 
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Introduction 133 
Pancreatic cancer (PC) remains the cancer with the lowest five-year survival rate (<7%).1,2 PC 134 
risk/protective factors include a constellation of medical conditions, such as diabetes, chronic 135 
pancreatitis, obesity, allergies and asthma, some lifestyle-related factors (smoking and heavy 136 
alcohol intake), non-O blood group, and family history (FH) of PC.3 Several of these medical 137 
conditions, as well as PC, may share inherited genetic factors but their relationships and 138 
interactions have largely not been explored. 139 
As many as 10% of all PCs are aggregated in families.4 Familial pancreatic cancer is 140 
defined as two or more first-degree relatives (FDRs) affected with PC that do not meet any known 141 
cancer syndrome criteria. It is the largest (80%) FHPC group and genetic susceptibility explains 142 
less than 15% of the PC familial clustering, owing to the genetic heterogeneity of this disease.5  143 
Findings from several epidemiological studies, including a meta-analysis of nine studies,6 144 
support that FHPC confers an increased PC risk among FDRs.7–15 However, there is variability on 145 
the reported risk estimates despite all attempts to assess PC risk associated with FHPC.  146 
In addition to PC, familial aggregation of other cancers, such as colorectal and breast, has 147 
been shown to be associated with an increased PC risk.8,10,12,14 Mutations in genes responsible for 148 
hereditary cancer syndromes (i.e., BRCA1/2) may partly explain these associations.4 149 
There is a need to better characterize the associations aforementioned to deepen our 150 
understanding on the underlying mechanisms of pancreas carcinogenesis. The current state of 151 
knowledge is, indeed, limited owing to drawbacks of earlier studies assessing familial-associated 152 
PC risk. Their reported differences in risk estimates are likely attributable to the inappropriate 153 
assessment of lifetime risks of PC among relatives.16,17  Concerns have also been raised regarding 154 
failure to adjust for smoking or other potential confounders.6 Non-genetic risk factors shared in the 155 
family environment may, indeed, contribute to familial cancer aggregation. Furthermore, given that 156 
several of the non-cancer co-morbidities associated with PC also present a heritable component,18 157 
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it would be important to explore the contribution of the latter to the risk of PC. Their impact on the 158 
development of specific PC phenotypes is another under-investigated subject. Until now, only two 159 
studies have addressed the association between FH of diabetes (FHD) and PC risk.19,20 While 160 
these studies showed that FHD implies a greater PC risk, they also encountered several types of 161 
bias, casting doubt upon the reliability of these previous findings. 162 
Our aim was to comprehensively assess these issues within the largest and most 163 
informative study of PC conducted to-date, which enabled us to perform a case-control study and 164 
to apply other novel design approaches, such as reconstructed relative cohort assessments. 165 
 166 
 167 
Methods 168 
Study population: 169 
The European Study into Digestive Illnesses and Genetics (PanGenEU) is a large multicentric 170 
case-control study that was initiated in 2009 in six European countries (Spain, Italy, Germany, United 171 
Kingdom, Sweden and Ireland) to identify relevant risk factors of PC including lifestyle and environmental 172 
factors, biomarkers of exposure to these factors, and genetic factors. All potential eligible PC cases were 173 
recruited to overcome selection bias attributable to the rapid progression of the disease. Diagnosis 174 
of all included cases was verified thereafter through review of medical records. Eligible controls 175 
were subjects free of PC and of any conditions related to known PC risk factors. The final analytic 176 
sample comprised 1,431 cases and 1,090 controls with information available on FH of cancer and FH of 177 
chronic pancreatitis, and 1,258 cases and 800 controls with information available on FH of the remaining 178 
diseases. Data from Italy was excluded beforehand because no data was available for Italian controls. 179 
All subjects provided written informed consent and the study was approved by the Ethical 180 
Committees of the participating centers. More details are provided in Supplementary Methods.  181 
 182 
Data collection of FH and other variables:  183 
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All participating centers applied the same recruitment protocols and questionnaires. Information on the 184 
occurrence of diseases (cancer, diabetes, allergies, asthma, chronic pancreatitis and cystic 185 
fibrosis) in FDRs of the cases and controls was collected through face-to-face interviews conducted 186 
by trained monitors. For FDRs with FHC additional information about the cancer sites and age at 187 
every cancer diagnosis was gathered (Supplementary Methods). Information on age at diagnosis 188 
was also collected for FDRs with diabetes (in categories: childhood/youth and adulthood). Cases 189 
and controls were also inquired about the vital status of every FDR, their current age (or age at 190 
death) and whether they had ever smoked.  191 
FH variables of these diseases were derived, along with variables by relative type and 192 
number of affected relatives. Composite score variables that combined number and type of 193 
relatives affected with the disease were also obtained. For FHC and FHD we also considered 194 
occurrence of either early or late-onset disease in relatives. 195 
Cases and controls also provided information about exposures to PC known and suspected 196 
risk factors (Supplementary Methods). In addition, clinical data of the tumors were collected for a 197 
subset of PC cases (n=504).  198 
 199 
Statistical analysis: 200 
Two approaches were carried out to explore the association between FH of the diseases and PC 201 
risk (Supplementary Methods): 202 
1) Case-control study. We used unconditional logistic regression to estimate odds ratios 203 
(ORs) and 95% confidence intervals (CIs) corresponding to PC risk associated with a positive FH 204 
(versus a negative FH) of cancer and other diseases. ORs were obtained for each FH variable. 205 
Potential confounding variables evaluated were: age (continuous), sex (female, male), country (Spain, Italy, 206 
Germany, United Kingdom, Sweden, and Ireland), smoking status (non-smokers and tertiles of pack-years 207 
for former and current smokers), BMI (normal weight - <25 kg/m2, overweight - ≥25-30 kg/m2, obesity - ≥30 208 
kg/m2), and self-reported diabetes status (no, yes ≤ 2 years, yes  > 2 years since diagnosis of diabetes), 209 
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educational level (< 5, 5 to 10, 11 to 13, > 14 years of education), asthma (no, yes), chronic pancreatitis (no, 210 
yes), nasal and skin allergies (no, yes), as well as FHPC (no, yes, FH of other cancers). These variables 211 
were added to age, sex and country adjusted models (Model 1). Variables changing the OR in more than 212 
10% (BMI, diabetes and FHPC) were retained (Model 2). We additionally controlled for the number of 213 
relatives to account for the effect of family size, a major issue in family-based studies,16  in a separate model 214 
(Model 3). 215 
Effect modification by country, smoking (never, former, current), diabetes (yes, no), BMI (normal, overweight 216 
and obesity), sex and age at cancer diagnosis (<50, ≥50 years), as well as FHPC and FHD, was evaluated 217 
by comparing models with and without an interaction term between these variables and FH by means of the 218 
likelihood ratio test (LHR) statistic.  219 
Heterogeneity by country was evidenced and random effects for country were therefore considered 220 
in mixed models.21 We also examined whether the associations varied by stage and location of the 221 
tumor, using the same control population for each strata.  222 
2)  Reconstructed-cohort study. For each case- and control-relative we calculated follow-up 223 
time as the time elapsed between birth (age=0) and the end of follow-up, defined by the reported 224 
age at cancer diagnosis, age at death or age at the interview date, whichever came first. Cumulative 225 
risks of cancer were calculated for both case-relatives and control-relatives cohorts using the 226 
Nelson-Aalen method and differences were evaluated with the log-rank test.22 Cox proportional 227 
hazard regression was used to obtain hazard ratios (HRs) and 95% CIs associated with cancer 228 
occurrence (overall and by cancer types) for the case-relatives (versus the control-relatives), 229 
stratified by sex, age (1-year intervals) and relative type, using for the latter a robust sandwich 230 
estimate of the covariance matrix.23 In addition, we accounted for heterogeneity by country by using 231 
a frailty for this variable in the model.24 Potential confounding and effect modification by other covariates 232 
(the relatives’ smoking status and occurrence of diseases, age, sex and the type of relative) was likewise 233 
assessed by evaluating changes in the HR estimate above 10% and testing interaction via the LHR, 234 
respectively. 235 
 236 
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For both approaches we conducted sensitivity analyses including generalized estimating equation 237 
(GEE) regression23 to ensure the robustness of our results (Supplementary Methods). We handled 238 
imputation of missing data (Supplementary Methods and Supplemental Table 1) with the random 239 
forest algorithm.25 Assumptions of logistic regression analyses were met as indicated by the 240 
Hosmer-Lemeshow goodness-of-fit test.26 The proportional hazards assumption was also met as 241 
indicated by the Schoenfield residuals plots of each covariate.27  242 
Statistical software used for the data analysis was R 3.2.1.28 243 
 244 
Results 245 
Case-control approach 246 
The study population characteristics are shown in Table 1. Cases were more frequently smokers 247 
and diabetics and had a smaller family size as compared to controls. The proportion of positive 248 
FHC, FHPC and of FHD was also higher among cases than in controls.  249 
Risk estimates of PC associated with FHC and FH of other diseases are shown in Tables 250 
2 and Table 3, respectively. A statistically significant positive association was observed in 251 
multivariate-adjusted models evaluating PC risk associated with a positive versus negative FHC 252 
(OR=1.30, 95%CI: 1.13-1.54). This increased PC risk was more pronounced in parents and 253 
siblings, and in advanced-aged FDRs. PC risk also increased with increasing number of relatives 254 
with cancer (p-trend=0.003). Analyses by cancer site also revealed statistically significant 255 
associations with FHPC (OR=2.68; 95%CI: 2.23-4.06), as well as for FH of breast & ovary, 256 
colorectal, prostate and smoking-related cancers (OR=1.45; 1.27; 1.70; 1.34, respectively). The 257 
trend of the association across types of relatives and number of affected relatives was similar to 258 
that observed for FHC overall (data not shown). In particular, PC risk was nearly four-fold increased 259 
(OR=3.88; 95%CI: 2.97-9.72) when >2 FDRs were affected with PC (Table 2). 260 
FHD was associated with a 24% (95%CI: 1.01-1.52) higher PC risk, an effect that was 261 
mostly driven by adult-onset diabetes. The PC risk increased with the number of FDR affected with 262 
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diabetes (OR=1.51; 95%CI: 1.22-1.87). No significant associations with PC risk were encountered 263 
for the occurrence of other co-morbidities in the family, although prevalence of FHCF and FHCP 264 
was probably too low to derive precise estimates (Table 3). Overall, family size had a negligible 265 
impact on the risk estimates. 266 
Risk of PC associated with FHPC was higher among ever-smokers (OR=3.16, 95%CI: 267 
2.56-5.78, interaction p-value=0.04) (Supplemental Table 2) with current and former smokers with 268 
FHPC exhibiting an even higher PC risk with respect to never smokers without FHC (OR~5) 269 
(Supplemental Table 3, Supplemental Figure 1). Risk estimates remained the same in ever-270 
smokers after additionally controlling for smoking intensity and duration (data not shown).  271 
PC cases with >2 affected FDRs with PC were more likely to present early-stage tumours 272 
(Supplemental Table 4). Conversely, having a single FDR with PC was found to be associated with 273 
a significant increased risk of late-stage tumours (OR=2.36, 95%CI: 1.67-4.73). Further, risk of late-274 
stage PC tended to be positive for those having a FHD, whereas the association turned inverse for 275 
early-stage tumours (OR=0.63, 95%CI: 0.17-0.99), with differences in risk estimates by stage being 276 
statistically significant (p=0.003).  277 
We did not observe effect modification by location (Supplemental Table 4) or any other 278 
variable (data not shown). Risk estimates remained almost unchanged in sensitivity analyses 279 
(Supplemental Table 5). 280 
 281 
Reconstructed-cohort approach 282 
Two cohorts were reconstructed with a total of 9,055 case-relatives and 7,360 control-relatives 283 
contributing with 509,801 and 414,309 person-years to the cancer overall analyses (Supplemental 284 
Tables 6 and 7). Characteristics of case-relatives and control-relatives are shown in Table 1. Case-285 
relatives had been more frequently ever smokers than control-relatives. Aggregation of cancer 286 
events including PC was also higher in case-relatives.  287 
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The cumulative risk of cancer by age 75 was of 23.8% in case-relatives and 19.5% in 288 
control-relatives (HR=1.16, 95%CI: 1.05-1.29) (Figure 1). Corresponding risks for PC were 2.2% 289 
and 0.7%, respectively (HR=2.4, 95%CI: 2.16-2.71). HRs of similar magnitude were also observed 290 
for multiple primary cancers. Cancers of the breast & ovary, prostate and those regarded as 291 
smoking-related were also more likely to aggregate among case-relatives than control-relatives 292 
(HR=1.14, 1.66 and 1.24, respectively).  293 
Interaction analyses by age, relative type and smoking were not statistically significant 294 
(Supplemental Table 6). There was a differing aggregational relationship between cancer and PC 295 
in case-relatives compared to control-relatives by diabetes status (p-value for interaction=0.03), 296 
which was not manifested in other cancer sites. Results were consistent across all sensitivity 297 
analyses conducted (Supplemental Table 7). 298 
 299 
 300 
Discussion 301 
In this study, we characterized PC risk associated with FH of cancer and PC-associated co-302 
morbidities by applying, for the first time, two complementary strategies: a standard case-control 303 
study and a reconstructed-cohort approach to deal with potential bias due to differential relative´s 304 
lifetime risk between cases and controls. In addition, we considered the effect of smoking and other 305 
familial shared risk factors so as to better address the contribution of inherited versus environmental 306 
factors on the familial aggregation of the diseases. Our findings point to a 2.7-fold increased risk of 307 
PC associated with a positive FHPC. They also suggest a positive association between FHD and 308 
FH of certain cancer types with PC risk. The excess risks increased with the number of affected 309 
relatives, i.e., PC risk increased by nearly four times when ≥2 FDRs were affected with PC.  310 
Existing evidence support that FHPC increases PC risk. Our risk estimates are close to 311 
those reported by a meta-analysis including 2,617 cases and 6,284 controls (OR=2.82; 95%CI: 312 
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1.99–3.66),6 and other case-control studies,14,15 but higher when compared with few other cohort-313 
based studies.11,12 Our finding that subjects with ≥2 FDRs with a PC diagnosis have a higher PC 314 
risk are consistent with other studies showing similar risk estimates,11 but of lower magnitude with 315 
regard to that of Klein et al.7 Also, PC risk was increased for late-onset cancer in FDRs. Fewer 316 
cases and controls were available for analyses evaluating PC risk associated with early-onset 317 
cancers in the family to confirm the stronger association reported in previous studies.8,10,12   318 
Reasons for the varying risk estimates of PC associated with FHPC include issues inherent 319 
to study design. Criticism has been raised when using case-control studies to assess the 320 
association between FH and disease risk due to differences in the number of relatives among cases 321 
and controls leading to dissimilar age distributions and inadequate assessment of the relatives´ 322 
lifetime risk.17,18 The reconstructed cohort strategy has been proposed as a better approach to 323 
evaluate FH as a risk factor of disease,16 albeit both seem to be equally valid.17 Comparable results 324 
were achieved in our study using both approaches, which reinforces the described associations. 325 
Our findings suggest a positive association between FH of prostate, colorectal, breast & 326 
ovary, and smoking-related cancers with PC risk. Other studies have also reported that FH of some 327 
cancer types increase PC risk.9,13,14  Likewise, relatives of PC cases seem to have a higher risk of 328 
developing other cancers.29 Previous studies assessing these associations did not consider FH of 329 
other cancers, some of which seem to contribute to PC risk, as a separate risk category. In fact, 330 
risk of PC dropped in our study if the reference category included positive FH of other cancers 331 
(Table 1). The positive association between FH of prostate cancer and PC risk was reported 332 
earlier,12 as well as that of the other cancer sites,8 supporting that certain cancer types in the family 333 
increase susceptibility to develop PC. These potential associations between FHC and PC risk may 334 
signal underlying common genetic and/or environmental risk factors. Indeed, known mutations in 335 
several high-penetrance genes (e.g. BRCA2, PALB2, ATM, among others) as well as newly 336 
identified genetic variants have been all linked to familial PC and the aforementioned cancers.5,28 337 
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Exposure to smoking in the family environment seemed to not influence the association between 338 
FH and PC risk but whether sharing of other environmental exposures such as dietary habits or 339 
overweight/obesity would trigger PC remains an open question. 340 
Unlike most previous studies,6 we addressed the importance of environmental factors on 341 
the association between FHC with PC risk by adjusting risk estimates for smoking and other factors. 342 
We observed a higher excess risk of PC in smokers with FHPC, which was also reported in 343 
some,6,10  but not all previous studies.11 The lack of an interaction between FHPC and smoking in 344 
the cohort could be due to sample size issues, or the inaccurate reporting of the relatives´ smoking 345 
status. Loss to follow-up could be another issue despite the fact that we reached acceptable follow-346 
up rates (89%).31 Adjusting for diabetes had a modest impact on risk estimates and it did not modify 347 
the PC-risk effect in the case-control study. 348 
Our results on the association between FHD and PC risk are in agreement with those of a 349 
case-control (OR=1.37; 95%CI: 1.10–1.71),20 and a population-based study (SIR=2.98; 95%CI: 350 
2.85-3.11).19 While diabetes genetic susceptibility variants associated with PC risk have not been 351 
identified,32 their existence is plausible due to the well-established link between diabetes and PC 352 
risk.3  353 
Our study presents some limitations. While our estimates rely on self-reported disease 354 
occurrence in the family, this information seems to be reliable either regarding common 355 
malignancies, or pancreatic cancer,33 as well as diabetes.34 Irrespective of these facts, 356 
misclassification of the exposure cannot be discarded. Also, we cannot preclude the possibility of 357 
having included benign tumours or metastatic sites as primary cancers. Occurrence of multiple 358 
primary cancers as a consequence of previous cancer treatments or genetic and non-genetic 359 
factors triggering subsequent cancers is another consideration to be taken into account. Our 360 
sensitivity analyses and the procedures adopted, however, indicate that these circumstances 361 
should not have affected our results. 362 
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The study also has multiple strengths. This is the first large case–control study addressing 363 
the association between FHC, FHPC and FH of non-cancer co-morbidities with PC risk. Another 364 
outstanding feature is the two different approaches used to evaluate these associations. Our study 365 
is also the first considering characteristics of the cases and controls and relatives thereof, ruling 366 
out bias due to unmeasured confounding. In fact, characterizing these associations by accounting 367 
for the contribution of environmental factors is of utmost importance to define PC prevention 368 
actions. Equally important is to investigate clinical features of familial associated-PC in order to 369 
foster the development of early detection strategies. For instance, our results point towards the 370 
existence of different phenotypes in PC patients with FHD or FHPC.  371 
 372 
In conclusion, we confirm using two independent analytical strategies that FHPC and FHC 373 
are associated with an increased PC risk. Furthermore, we provide evidence that FHD is also 374 
associated with a modest increase in PC risk. Together, our findings call for further research to 375 
advance our understanding on how to reduce the PC burden in families at higher risk of PC. 376 
  377 
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 473 
Table 2: Odds Ratios and 95% confidence intervals (CIs) of pancreatic cancer (PC) associated 474 
with family history (FH) of cancer overall, FH of pancreatic cancer (FHPC) and FH of other cancer 475 
types. 476 
 477 
Table 3: Odds Ratios and 95% confidence intervals (CIs) of pancreatic cancer (PC) associated 478 
with family history (FH) of other medical conditions (diabetes, asthma, allergies, cystic fibrosis, and 479 
chronic pancreatitis). 480 
 481 
Figure 1: Cumulative risk of cancer and cancer types including pancreatic cancer (PC) comparing 482 
case-relatives and control-relatives. In all panels, black lines show the data based on case-relatives 483 
whereas the grey lines that of the control-relatives. P-values corresponding to log-rank tests 484 
comparing survival curves and cumulative risks to age 75 years are indicated in shaded boxes, 485 
along with Hazard Ratios (HR) and 95% confidence intervals (CIs) of PC associated with familial 486 
aggregation of cancer for case-relatives versus control-relatives. Sex-specific cumulative risks are 487 
presented for prostate and ovarian&breast cancer. 488 
 489 
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Table 1: Baseline characteristics of the 1,431 cases and 1,090 controls of the PanGenEU study, and that 516 
of their corresponding relatives. 517 
 518 
Case-control approach Cases Controls p-value* 
Age, mean ± SD 65.4 ± 11.7 65.6 ± 13.1 0.74 
Men, N (%) 809 (56.6) 569 (52.3) 0.03 
Obese, BMI ≥ 30 kg/m2, N (%) 292 (21.8) 218 (21.3) 0.96 
Ever smokers, N (%) 858 (60.0) 555 (50.9) <0.001 
Number of cigarretes smoked, mean ± SD 25.3 ± 44.9 16.5 ± 30.3 <0.001 
Diabetes, N (%) 362 (25.3) 140 (12.8) <0.001 
Asthma, N (%) 99 (7.2) 115 (10.8) 0.002 
Atopic diseases, N (%) 265 (18.5) 293 (26.9) 0.001 
Chronic pancreatitis, N (%) 9 (0.7) 1 (0.1) 0.05 
Family size and characteristics †    
Number of relatives, mean (range) 6.1 (0-23) 6.5 (0-22) 0.01 
Age of the father, mean ± SD 51.5 ± 14.9 51.8 ± 14.1 0.92 
Father ever smoked, N (%) 928 (64.8) 726 (66.6) 0.91 
Age of the mother, mean ± SD 59.1 ± 14.0) 58.6 ± 14.5 0.47 
Mother ever smoked, N (%) 203 (14.2) 167 (15.3) 0.77 
Number of siblings, mean (range) 4.1 (0-18) 4.4 (0-16) 0.01 
Number of offspring, mean (range) 3.1 (0-11) 3.2 (0-14) 0.97 
Cohort approach ¥ Case-relatives Control-relatives p-value 
Age, mean ± SD 57.0 ± 21.0 56.9 ± 21.2 0.90 
Men, N (%) 4,671 (50.8) 3,794 (50.6) 0.88 
Alive, N (%) 6,027 (65.9) 4,902 (66.2) 0.77 
By relative type   0.05 
    Parents, N (%) 2,634 (28.5) 2,031 (27.0)  
    Siblings, N (%) 3,855 (41.8) 3,285 (43.4)  
    Offspring, N (%) 2,713 (29.4) 2,178 (29.0)  
Ever smokers, N (%) 5,494 (59.5) 3,820 (50.8) <0.001 
Diabetes, N (%) # 598 (8.1) 350 (7.6) 0.34 
Asthma, N (%) # 387 (5.2) 220 (4.7) 0.26 
Allergies, N (%) # 571 (7.8) 326 (7.1) 0.19 
Cystic fibrosis, N (%) # 16 (0.2) 8 (0.2) 0.76 
Chronic pancreatitis, N (%) 51 (0.6) 33 (0.5) 0.34 
Cancer aggregation among relatives    
Cancer, N (%) 1,316 (15.7) 893 (13.2) <0.001 
Mean age at diagnosis ± SD 63.3 ± 28.7 63.5 ± 34.1 0.88 
Mean follow-up in years ± SD 56.2 ± 20.8 56.2 (21.2) 0.96 
Person-years 509,811 414,309  
PC, N (%) 107 (1.3) 35 (0.5) <0.001 
Mean age at diagnosis ± SD 67.0 ± 11.3 66.9 ± 14.1 0.96 
Mean follow-up in years ± SD 57.0 ± 21.0 56.9 ± 21.2 0.99 
Person-years 525,691 428,030  
 
Colorectal cancer, N (%) 214 (2.0) 151 (2.3) 0.43 
Mean age at diagnosis ± SD 63.7 ± 11.7 65.8 ± 13.5 0.14 
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Mean follow-up in years ± SD 69.1 ± 12.1 69.6 (13.5) 0.70 
Person-years 522,912 425,972  
Prostate cancer (men), N (%) 114 (1.2) 58 (0.8) 0.01 
Mean age at diagnosis ± SD 69.6 ± 9.6 71.4 ± 9.2 0.30 
Mean follow-up in years ± SD 74.6 ± 9.7 75.9 (9.4) 0.42 
Person-years (men) 259,671 212,584  
Breast and ovarian cancer (women), N (%) 177 (1.9) 136 (1.8) 0.89 
Mean age at diagnosis ± SD 57.36± 14.5 54.7 ± 14.6 0.11 
Mean follow-up in years ± SD 65.6 ± 14.9 64.4 (15.0) 0.47 
Person-years (women) 263,037 212,571  
Smoking-related cancers, N (%) 740 (8.0) 465 (6.2) <0.001 
Mean age at diagnosis ± SD 64.4 ± 12.9 65.0 ± 13.4 0.44 
Mean follow-up in years ± SD 67.9 ± 12.9 68.3 (13.3) 0.67 
Person-years 518,055 421,983  
Multiple primary cancers, N (%) 759 (8.2) 490 (6.5) <0.001 
Mean age at diagnosis ± SD 67.3 ± 34.3 68.0 ± 42.1 0.76 
Mean follow-up in years ± SD 71.1 ± 13.6 71.1 (13.6) 0.50 
Person-years 509,801 414,309  
 519 
*p-values were based on Wilcoxon rank-sum test for continuous variables, and chi-squared test for categorical variables (two-sided).  520 
 521 
†Family size count excluded the index case and control subject.  522 
Age at the date of the interview. Age at death was considered for those FDRs who died before the interview.   523 
 524 
# Cases and controls from Ireland were excluded for analyses on FHD, FHAS, FHAL and FHCF; there were 1,258 cases and 800 525 
controls available for these analyses. 526 
 527 
The numbers do not sum up due to missing data.  528 
 529 
  530 
Molina-Montes et al. Ms FH and PC (01.08.2017) 
 
Table 2: Odds Ratios and 95% confidence intervals (CIs) of pancreatic cancer (PC) associated with family 531 
history (FH) of cancer overall, FH of pancreatic cancer (FHPC) and FH of other cancer types. 532 
 Cases (%) Controls (%) Model 1 
OR (95 % CI) 
Model 2 
OR (95 % CI) 
Model 3 
OR (95 % CI) 
FH Cancer (FHC) 
No 552 (38.6) 481 (44.1) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
Yes 879 (61.4) 609 (55.9) 1.27 (1.10-1.49) 1.29 (1.12-1.52) 1.30 (1.13-1.54) 
Age at earliest cancer diagnosis in relatives  
No FHC 552 (38.6) 481 (44.1) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
FHC < 50 years 126 (8.8) 94 (8.6) 1.20 (0.89-1.62) 1.16 (0.84-1.58) 1.16 (0.85-1.59) 
FHC ≥ 50 years 753 (52.6) 515 (47.2) 1.27 (1.10-1.51) 1.30 (1.13-1.55) 1.32 (1.14-1.58) 
Number of affected relatives with cancer        
No FHC 552 (38.5) 481 (44.1) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
1 FDR 536 (37.5) 380 (34.9) 1.24 (1.05-1.49) 1.25 (1.06-1.51) 1.26 (1.07-1.52) 
≥ 2 FDRs 343 (23.9) 229 (21.0) 1.32 (1.10-1.63) 1.34 (1.12-1.68) 1.37 (1.15-1.72) 
     p-trend: 0.003 
FHC in Parents         
No FHC 830 (58.0) 667 (61.2) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
Yes in parents 601 (42.0) 423 (38.8) 1.11 (0.94-1.31) 1.14 (0.97-1.35) 1.14 (0.98-1.35) 
FHC in Siblings         
No FHC 1020 (71.3) 814 (74.7) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
Yes in sibblings 411 (28.7) 276 (25.3) 1.28 (1.09-1.54) 1.28 (1.09-1.55) 1.32 (1.12-1.61) 
FHC in Offspring         
No FHC 1369 (95.7) 1044 (95.8) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
Yes in offspring 62 (4.3) 46 (4.2) 1.02 (0.62-1.54) 1.05 (0.64-1.59) 1.06 (0.65-1.60) 
FH Risk Score1           
No FHC 552 (38.5) 481 (44.1) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
1-2 751 (52.5) 528 (48.4) 1.23 (1.06-1.46) 1.25 (1.08-1.48) 1.26 (1.08-1.50) 
3-4 91 (6.3) 62 (5.7) 1.30 (0.94-1.86) 1.36 (0.99-1.96) 1.39 (1.02-2.03) 
5-6 13 (0.9) 6 (0.6) 2.08 (1.08-5.70) 2.41 (1.41-6.53) 2.45 (1.46-6.66) 
     p-trend: 0.002 
FH Pancreatic Cancer      
No FHPC (but FH other cancers) 1327 (92.7) 1054 (96.7) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
Yes FHPC 104 (7.3) 36 (3.3) 2.39 (1.99-3.56) 2.39 (1.99-3.58) 2.40 (2.00-3.59) 
FH Pancreatic Cancer       
No FHC 552 (38.6) 481 (44.1) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
Yes FHPC 104 (7.3) 36 (3.3) 2.63 (2.22-3.96) 2.65 (2.24-4.01) 2.68 (2.27-4.06) 
Yes FH other cancers 775 (54.1) 573 (52.6) 1.18 (1.01-1.40) 1.20 (1.03-1.43) 1.21 (1.04-1.44) 
Age at PC diagnosis in relatives 
FHPC < 50 years 7 (0.5) 3 (0.3) 1.85 (0.43-7.62) 1.97 (0.54-8.23) 2.03 (0.60-8.52) 
FHPC ≥ 50 years 97 (6.8) 33 (3.0) 2.70 (2.27-4.12) 2.71 (2.28-4.16) 2.74 (2.31-4.21) 
Number affected relatives with PC 
1 FDR 76 (5.3) 30 (2.7) 2.37 (1.92-3.73) 2.41 (1.96-3.81) 2.43 (1.97-3.84) 
≥ 2 FDRs (FPC) 28 (1.9) 6 (0.6) 3.86 (2.95-9.57) 3.82 (2.90-9.55) 3.88 (2.96-9.73) 
     p-trend: 0.033 
Type of relative with PC           
Yes in Parents 68 (5.7) 21 (2.6) 2.54 (2.02-4.22) 2.65 (2.12-4.47) 2.64 (2.12-4.47) 
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Yes in Siblings 59 (4.1) 19 (1.7) 2.77 (2.23-4.75) 2.75 (2.20-4.75) 2.83 (2.28-4.90) 
Yes in Offspring 4 (0.3) 1 (0.1) 3.97(1.74-36.90) 3.91 (1.70-35.81) 3.95 (1.74-36.19) 
FH of other cancer sites 
Yes FH colorectal  188 (13.1) 130 (11.9) 1.29 (1.03-1.68) 1.27 (1.00-1.66) 1.28 (1.01-1.68) 
Yes FH prostate 102 (7.1) 57 (5.2) 1.53 (1.17-2.18) 1.68 (1.32-2.41) 1.71 (1.34-2.45) 
Yes FH breast & ovary 169 (12.0) 121 (11.2) 1.27 (1.00-1.67) 1.30 (1.03-1.72)  1.31 (1.03-1.73) 
Yes FH smoking-related  572 (40.0) 376 (34.5) 1.32 (1.13-1.58) 1.33 (1.14-1.61) 1.35 (1.15-1.63) 
Yes FH multiple primaries 755 (52.8) 497 (45.6) 1.30 (1.13-1.54) 1.33 (1.16-1.58) 1.33 (1.16-1.58) 
Model 1: sex, age and country-adjusted  
Model 2: additionally adjusted for smoking in pack-years (non-smokers, and tertiles of pack-years for former and current 
smokers), BMI (normal weight, overweight, obesity), and self-reported diabetes status (no, yes ≤ 2 years, yes  > 2 years since 
diagnosis of diabetes)  
Model 3: additionally adjusted for number of relatives (family size)  
 
Analytic sample size was based on 1,431 PC cases and 1,090 controls.  
 
Reference category is “negative FH of any cancer” for cancer overall and for every cancer site, unless stated otherwise. For site-
specific analyses, we considered other cancers in a separate category; these results are not shown as they resemble those 
reported for FH of cancer overall.  
 
 P-value for trends across strata was evaluated by fitting linear models.  
 
1 Composite score variable calculated by summing up points that were assigned proportionally to the number of affected FDRs 
in each type of relative: 2 points if there were more than 2 FDRs affected, 1 point if there was 1 FDR affected and 0 points if 
there was not any FDR affected. The score ranged from 0 to 6 points. 
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Table 3: Odds Ratios and 95% confidence intervals (CIs) of pancreatic cancer (PC) associated with family 536 
history (FH) of other medical conditions (diabetes, asthma, allergies, cystic fibrosis and chronic pancreatitis). 537 
 Cases (%) Controls 
(%) 
Model 1  
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
FH Diabetes (FHD)¶ ¥ 
No  828 (65.8) 557 (69.6) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
Yes 430 (34.2) 243 (30.4) 1.28 (1.05-1.56) 1.25 (1.02-1.52) 1.24 (1.01-1.52) 
Age at diabetes diagnosis in relatives 
No FHD 828 (65.8) 557 (69.6) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
Yes in youth 29 (2.3) 29 (3.6) 0.69 (0.16-1.18) 0.70 (0.16-1.20) 0.69 (0.16-1.19)  
Yes in adulthood 401 (31.9) 214 (26.7) 1.30 (1.10-1.59) 1.27 (1.06-1.55)  1.26 (1.06-1.55) 
Number of affected relatives with diabetes 
No FHD 828 (65.8) 557 (69.6) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
Yes in 1 FDR 309 (24.5) 174 (21.8) 1.22 (1.01-1.52) 1.18 (0.96-1.47) 1.18 (0.96-1.47) 
Yes in ≥ 2 FDRs 121 (9.7) 69 (8.6) 1.25 (0.93-1.71) 1.24 (0.93-1.72) 1.24 (0.92-1.71)  
     p-trend:0.082 
FHD in Parents 
No FHD 952 (75.7) 630 (78.8) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
Yes in parents 306 (24.3) 170 (21.2) 1.22 (0.99-1.52) 1.17 (0.95-1.47) 1.17 (0.94-1.47) 
FHD in Siblings 
No FHD 1076 (85.5) 699 (87.4) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
Yes in siblings 182 (14.5) 101 (12.6) 1.23 (0.96-1.60) 1.20 (0.92-1.56) 1.19 (0.91-1.57) 
FHD in Offspring 
No FHD 1219 (96.9) 779 (97.4) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
Yes in offspring 39 (3.1) 21 (2.6) 1.26 (0.71-2.17) 1.29 (0.73-2.24) 1.28 (0.72-2.23) 
Diabetes Risk Score1 
No FHD 828 (65.8) 557 (69.6) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
1-2 338 (26.8) 196 (24.5) 1.18 (0.96-1.45) 1.14 (0.92-1.41) 1.13 (0.92-1.40) 
3-4 87 (6.9) 45 (5.6) 1.37 (1.11-1.69) 1.33 (1.08-1.65) 1.31 (1.06-1.61) 
5-6 5 (0.4) 2 (0.3) 1.87 (1.52-2.31) 1.55 (1.25-1.91) 1.51 (1.22-1.87) 
     p-trend:<0.001 
FH Asthma (FHAS) ¶ 
No 954 (75.8) 623 (77.9) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
Yes 304 (24.2) 177 (22.1) 1.11 (0.89-1.37) 1.07 (0.84-1.33) 1.06 (0.84-1.33) 
FH Allergies (FHAL) ¶ 
No 869 (69.1) 569 (71.1) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
Yes 389 (30.9) 231 (28.9) 1.11 (0.91-1.35) 1.06 (0.86-1.30) 1.06 (0.95-1.30) 
FH Cystic Fibrosis (FHCF) ¶ 
No 1244 (98.9) 793 (99.1) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
Yes 14 (1.1) 7 (0.9) 1.28 (0.36-3.23) 1.41 (0.47-3.60) 1.40 (0.47-3.58) 
FH Chronic Pancreatitis (FHCP)π 
No 1382 (96.6) 1057 (97.0) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 
Yes 49 (3.4) 33 (3.0) 1.19 (0.73-1.90) 1.04 (0.56-1.69) 1.05 (0.57-1.71) 
Model 1: sex-age and country-adjusted ORs. Model 2: additionally adjusted for smoking in pack-years (non-smokers-and tertiles of 
pack-years for former and current smokers), BMI (normal weight, overweight, obesity), family history of pancreatic cancer (no, yes , 
other cancer). Model 3: additionally adjusted for number of relatives (family size). 
P-value for trends across strata was evaluated by fitting linear models. 
¥ Multivariate-adjusted ORs included the same covariates except self-reported diabetes status.  
Molina-Montes et al. Ms FH and PC (01.08.2017) 
 
¶ Analytic sample was based on 1,258 PC cases and 800 controls.  
π Analytic sample was based on 1,431 PC cases and 1,090 controls. 
1 Composite score variable calculated by summing up points that were assigned proportionally to the number of affected FDRs in 
each type of relative: 2 points if there were more than 2 FDRs affected, 1 point if there was 1 FDR affected and 0 points if there was 
not any FDR affected. The score ranged from 0 to 6 points. 
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